TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03823001

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: virtual biopsy (VB) monitoring protocol
Description: 1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year.
Study: NCT05596565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise by a physiotherapist via face to face
Description: Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise by a physiotherapist via face to face
Description: Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference
Study: NCT04641078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600 mg BID

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study: NCT05479136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET imaging with 18F fluciclovine
Description: PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Study: NCT04641078

Intervention type: RADIATION
Group type: OTHER
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study: NCT05394649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: A new device has been designed by Shockwave Medical Inc. for the treatment of calcified vascular lesions to support stent delivery: the C2 Shockwave Medical® (IVL), Inc. coronary lithotripsy system. The system is based on lithotripsy to induce microfractures in the calcified plaque before low-pressure balloon dilation. The C2 Shockwave Medical® coronary lithotripsy (IVL) system consists of an IVL Catheter with two lithotripsy emitters enclosed within an integrated balloon, an IVL Generator, and an IVL Connector Cable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Atherectomy
Description: Rotational Atherectomy is a technique of calcic coronary plaque preparation based on the debulking of superficial calcium by a high-speed burr in order to improve vessel compliance and immediate vessel lumen gain before stenting.
Study: NCT05629897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sessions of cognitive stimulation
Description: 40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
Study: NCT06548087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gigstride Ambulatory Device
Description: For patients who are scheduled to be seen by the investigator in clinic with one of the above diagnoses, and recommended to use some type of ambulatory aid, the investigator will offer the Gigstride ambulatory device as an alternative and inquire about the patient's interest in participating in the study. After choosing to be a part of the study, the participant will use Gigstride device to perform the following tasks:~* Walk a different distances to assess speed and fatigue~* Perform functional mobility tasks (sit-to-stand, stand-to sit, stand-pivots, etc.)~The participant will then be asked to fill out a questionnaire, Gigstride Clinical Trial Questionnaire that will be used for qualitative data, such as ease of use and comfortability with using the device.~The overall amount of time for the evaluation and questionnaire will take approximately 30 minutes to 1 hour.
Study: NCT05139745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899 treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-899
Description: BTL-899 treatment
Study: NCT05824611

Intervention type: OTHER
Intervention: collect movement data from epileptic seizures
Description: non-invasive recording of movement data during care as usual
Study: NCT04734015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together Overcoming Diabetes (TOD)
Description: Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
Study: NCT05962762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group.
Study: NCT05443581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Dietary guidance will be given to participants through monthly face-to-face interviews and biweekly telephone calls to change their dietary structure and energy intake.
Study: NCT06169891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Description: one s.c. injection of SSGJ-613 once, on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
Study: NCT05670535

Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for dyspareunia
Description: Dyspareunia scores between 0 to 10 points

Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for dyspareunia
Description: Dyspareunia scores between 0 to 10 points

Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for vaginal dryness
Description: Vaginal dryness scores between 0 to 10 points

Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for vaginal dryness
Description: Vaginal dryness scores between 0 to 10 points

Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Description: Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points

Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Description: Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points

Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points

Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
Study: NCT04749238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
Study: NCT04326205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation, tDCS
Description: The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation, tDCS
Description: The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation, FES
Description: The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional electrical stimulation, FES
Description: The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no stimulation
Description: Both tDCS and FES will not be used in this section.
Study: NCT05792579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stoma closure
Description: early closure of stoma in trauma patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stoma closure
Description: early closure of stoma in trauma patients
Study: NCT06169891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Betamethasone Injection
Description: 1 mL i.m. once on Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
Study: NCT05160857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine
Description: The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
Study: NCT05871424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine patch group
Description: 5 mcg/h buprenorphine patch will be applied preoperatively

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo group
Description: simple dressing tape only will be applied
Study: NCT05097794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-1
Description: - Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-2
Description: - Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-1 + BR1015-2
Description: - Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
Study: NCT04784533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosing
Study: NCT05773807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bispectral index
Description: In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observer's assessment alert Sedation
Description: In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastroscopy
Description: Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastroscopy
Description: Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
Study: NCT06348251

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FoodSteps
Description: Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
Study: NCT04806061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: sodium bicarbonate 8.4% to achieve urinary pH \>7.5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care
Study: NCT05410925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT06049095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-001
Description: Oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses
Study: NCT06458062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket Colposcope
Description: Each patient will receive treatment in order to prevent cervical cancer
Study: NCT06262048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: 2 days pre-op, day of surgery, 2 days post-op

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 days pre-op, day of surgery, 2 days post-op
Study: NCT05740527

Intervention type: DEVICE
Group type: OTHER
Intervention: Noninvasive electrical stimulation of genital nerves
Description: A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
Study: NCT06463743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06339450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk tours
Description: * During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk tours
Description: * During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break.
Study: NCT05345405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic CARE
Description: Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporter-Only CARE
Description: Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
Study: NCT05818540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse novel CPAP mask
Description: Participants will wear the mask for 6 hours a night for 60 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed P-10 mask
Description: Participants will wear the mask for 6 hours a night for 60 days.
Study: NCT04723355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An innovative 3-lead wireless water resistant Holter device
Description: The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A conventional device
Description: The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
Study: NCT06285032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Description: Individuals will participate in a series of eight, 1hour weekly group sessions delivered by a study interventionalist who is a licensed social worker (see personnel list) using a HIPAA-compliant videoconferencing platform (Zoom). Each group will consist of 6-10 participants and participants randomized to this intervention will select between a series of date/time options. The investigators plan to run four groups with staggered start times. All participants will receive digital copies of the workbook for this intervention and each session, they will be given assignments to practice the strategies they learn during the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Navigation Group
Description: Those in the social navigation intervention, will meet with a navigator weekly through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 8 weeks. Each virtual visit will last approximately 30 minutes with a longer initial intake visit lasting 60 minutes. During the intake visit, the navigator will complete a patient narrative and an inventory of the patient's existing social network, former social network and interests. Using this, the navigator will work with the patient to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the 8 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection